CAMBRIDGE, Mass. and HOERSHOLM, Denmark, June 26, 2018 — Oncology Venture US Inc., Oncology Venture AB (OV:ST) (“OV”) and Medical...
Phase 1 Study of PARP Inhibitor 2X-121 Selected as Oral Presentation June 1, 2018 Hoersholm, Denmark and Cambridge, MA...
Cambridge, MA – October 25, 2017 — 2X Oncology, Inc. (“2X” or the “Company”), a precision medicine company developing...
— Developed DRP Successfully Identified Responders and Non-responders to Treatment with 2X-121 in 13-Patient Blinded Study — Cambridge, MA – August...
2X Oncology to conduct Phase 2 Study of 2X-121 in metastatic breast cancer patients Hoersholm, Denmark, and Cambridge, MA, July...
Cambridge, MA – June 8, 2017 — 2X Oncology, Inc. (“2X” or the “Company”), a precision medicine company developing targeted...
Cambridge, MA — May 31, 2017 — 2X Oncology, Inc. (“2X” or the “Company”), a company focused on developing...
CAMBRIDGE, Mass., May 30, 2017 — 2X Oncology, Inc. (“2X” or the “Company”), a company focused on developing targeted therapeutics...